Pfizer Inc. (PFE) Holdings Reduced by Benin Management CORP

Benin Management CORP reduced its stake in Pfizer Inc. (NYSE:PFE) by 6.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,974 shares of the biopharmaceutical company’s stock after selling 1,001 shares during the period. Benin Management CORP’s holdings in Pfizer were worth $654,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in PFE. OppenheimerFunds Inc. lifted its holdings in shares of Pfizer by 32.2% during the third quarter. OppenheimerFunds Inc. now owns 6,890,372 shares of the biopharmaceutical company’s stock worth $303,659,000 after purchasing an additional 1,678,438 shares during the period. Prio Wealth Limited Partnership lifted its holdings in shares of Pfizer by 3.2% during the third quarter. Prio Wealth Limited Partnership now owns 1,039,655 shares of the biopharmaceutical company’s stock worth $45,817,000 after purchasing an additional 32,071 shares during the period. Rehmann Capital Advisory Group lifted its holdings in shares of Pfizer by 1.4% during the third quarter. Rehmann Capital Advisory Group now owns 125,426 shares of the biopharmaceutical company’s stock worth $5,528,000 after purchasing an additional 1,759 shares during the period. Focused Wealth Management Inc lifted its holdings in shares of Pfizer by 160.7% during the third quarter. Focused Wealth Management Inc now owns 83,780 shares of the biopharmaceutical company’s stock worth $3,692,000 after purchasing an additional 51,644 shares during the period. Finally, Bradley Foster & Sargent Inc. CT lifted its holdings in shares of Pfizer by 1.4% during the third quarter. Bradley Foster & Sargent Inc. CT now owns 400,549 shares of the biopharmaceutical company’s stock worth $17,652,000 after purchasing an additional 5,393 shares during the period. Institutional investors own 69.49% of the company’s stock.

NYSE:PFE opened at $40.92 on Wednesday. The firm has a market cap of $250.26 billion, a PE ratio of 13.64, a PEG ratio of 2.51 and a beta of 0.75. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.57 and a quick ratio of 1.33. Pfizer Inc. has a 52-week low of $34.37 and a 52-week high of $46.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 29th. The biopharmaceutical company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.63 by $0.01. The firm had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.92 billion. Pfizer had a return on equity of 26.02% and a net margin of 20.79%. The firm’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.62 EPS. On average, analysts expect that Pfizer Inc. will post 2.86 EPS for the current fiscal year.

Several brokerages recently weighed in on PFE. Cantor Fitzgerald set a $53.00 price target on Pfizer and gave the stock a “buy” rating in a report on Sunday, December 30th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a report on Thursday, January 31st. Zacks Investment Research downgraded Pfizer from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Credit Suisse Group reaffirmed a “neutral” rating and set a $45.00 price target on shares of Pfizer in a report on Monday, January 28th. Finally, Bank of America raised their target price on Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a report on Monday, April 1st. One research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $45.61.

In other Pfizer news, EVP Dawn Rogers sold 15,002 shares of Pfizer stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $42.98, for a total value of $644,785.96. Following the completion of the sale, the executive vice president now owns 28,722 shares in the company, valued at approximately $1,234,471.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mikael Dolsten sold 149,553 shares of Pfizer stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $43.55, for a total value of $6,513,033.15. Following the completion of the sale, the insider now owns 390,097 shares of the company’s stock, valued at approximately $16,988,724.35. The disclosure for this sale can be found here. In the last quarter, insiders have sold 332,526 shares of company stock valued at $14,346,539. 0.09% of the stock is currently owned by company insiders.

WARNING: This report was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.com-unik.info/2019/04/17/pfizer-inc-pfe-holdings-reduced-by-benin-management-corp.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Systematic Risk

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit